CD133−/CD15+ xenograft tumor cells decreased to 9.6% in passage I, 10.3% in passage II and 5.9% in passage III (Figure 2B), suggesting that they may not be driving in vivo tumor formation. This evidence concerns the gene PROM1 and neoplasm.